Close

Anti-Peptide NYT T cell receptor (J15), pCDTCR1 (TCR-YC0946)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

TCR J15 is specific for H60, a dominant minor histocompatibility antigen. J15 TCR transgenic T cells express transgenic TCR β chains containing variable segments composed of Vβ8.3 (Vβ 13-1-02 according to the nomenclature defined in the international immunogenetics information system). Although expression of the transgenic TCR α chain could not be confirmed directly due to the lack of a suitable antibody to stain the transgenic Vα13D-1, staining with H60-tetamer confirmed expression of transgenic TCR by recognizing the H60 peptide/H-2Kb complex. Furthermore, negative selection of thymocytes expressing the J15 TCR in the thymus where H60 is ubiquitously expressed verified the specificity of the J15 TCRs.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide NYT
  • Epitope
  • LTFHYRNL
  • Format
  • Non-Modified TCR
  • Allele
  • H2-Kb
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • J15
  • Host Species
  • Mouse

Target

  • Introduction
  • Minor histocompatibility antigens are MHC-bound peptides and contribute to the generation of allo-responses after allogeneic transplantation. H60 is a dominant minor H antigen that induces a strong CD8 T-cell response in MHC-matched allogeneic transplantation settings.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide NYT T cell receptor (J15), pCDTCR1 (TCR-YC0946). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.